Israel
Brainsgate is an Israeli medical device company founded in 2002, dedicated to developing innovative therapies for patients with Central Nervous System (CNS) diseases. The company's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a key nervous center identified for its ability to increase cerebral blood flow.
Currently, BrainsGate is focusing on two main applications for its technology: the treatment of acute ischemic stroke and chronic SPG stimulation for vascular dementia patients. The company has garnered significant attention and support, including a recent Series F investment of $14.00M in December 2020. Notably, the investment was backed by prominent firms such as Spero Ventures, Pitango Venture Capital, Cipio Partners, Elron Ventures, BNP Paribas, Medtronic, and Agate Medical Investments.
With its strong focus on leveraging technology for medical advancements in the Biotechnology, Health Care, Health and Wellness, Internet, and Medical Devices industries, BrainsGate presents a compelling investment opportunity for those seeking to support breakthroughs in neurological treatments.
